Insider Trading April 21, 2026 10:16 AM

Synaptics Executive Sells $411K in Stock; Company Posts Q2 Beat

Senior vice president Ganesan Satish completed a scheduled sale under a 10b5-1 plan and a tax-withholding disposition tied to RSU settlement as Synaptics reports stronger-than-expected fiscal Q2 results

By Maya Rios SYNA
Synaptics Executive Sells $411K in Stock; Company Posts Q2 Beat
SYNA

Ganesan Satish, Senior Vice President and Chief Strategy Officer at Synaptics Inc., sold two blocks of company stock in mid-April 2026. One sale on April 20 was executed under a pre-established 10b5-1 trading plan; a separate April 17 disposition satisfied tax withholding on settled restricted stock units. The company also reported fiscal second-quarter results that topped analyst expectations for both earnings per share and revenue, though the stock dipped in after-hours trading.

Key Points

  • Ganesan Satish sold 5,065 shares on April 20, 2026 at $81.22 per share under a 10b5-1 trading plan, totaling about $411,379.
  • On April 17, 2026 Mr. Satish disposed of 5,862 shares at $80.22 per share, valued at about $470,249, to satisfy tax withholding for settled restricted stock units.
  • Synaptics reported fiscal Q2 2026 EPS of $1.21 and revenue of $302.5 million, both above analyst projections, although the stock fell in after-hours trading.

Ganesan Satish, Senior Vice President, General Manager Edge Interface & Sensing Division, and Chief Strategy Officer at SYNAPTICS Inc (NASDAQ:SYNA), completed two separate transactions involving the company’s common stock in April 2026.

On April 20, 2026, Mr. Satish sold 5,065 shares at a price of $81.22 per share, generating proceeds of approximately $411,379. That sale was carried out pursuant to a 10b5-1 trading plan he established on September 11, 2025.

Earlier in the week, on April 17, 2026, Mr. Satish disposed of 5,862 shares at $80.22 per share. That transaction totaled roughly $470,249 and represented shares withheld by Synaptics to satisfy tax withholding obligations associated with the settlement of restricted stock units.

After these transactions, Mr. Satish continues to hold a direct stake of 65,750 shares of Synaptics common stock.


Separately from the insider transactions, Synaptics reported fiscal second-quarter 2026 results that exceeded analyst expectations. The company posted earnings per share of $1.21 versus a forecast of $1.15, marking a surprise of 5.22%. Revenue for the quarter came in at $302.5 million, higher than the projected $300.05 million.

Despite the upside relative to analysts' estimates, Synaptics’ stock declined in after-hours trading following the release. The company’s ability to continue delivering results above projections remains the focus for investors and market watchers.

According to InvestingPro analysis, the stock is trading near its Fair Value and analysts maintain a bullish outlook. The platform notes that investors can access 11 additional ProTips and a set of comprehensive financial metrics for SYNA through its service.

The combination of insider activity and the quarter’s financial results underscores ongoing attention on Synaptics’ performance. The transactions by Mr. Satish included both a planned sale under a formal trading arrangement and a withholding-related disposition tied to equity compensation settlement.

Market participants will be tracking subsequent updates from the company and analyst commentary as they assess the implications of the earnings beat and the executive-level transactions for Synaptics’ near-term prospects.

Risks

  • Insider selling can be interpreted variably by the market; this includes potential short-term pressure on the stock - relevant to equity and technology sectors.
  • Despite earnings and revenue beats, the after-hours decline signals uncertainty in market reaction to results - relevant to investors assessing short-term price volatility.
  • Reliance on equity-based compensation settlements that trigger share withholding affects executive share counts and may complicate interpretation of insider activity - relevant to corporate governance and investor relations.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026